FDA Inspection 1016270 — ASRI-WPAHS IRB
The FDA completed an inspection of ASRI-WPAHS IRB on May 23, 2017 in Pittsburgh, PA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- May 23, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Pittsburgh, PA (United States)
Additional Details
IRB